Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Retained Earnings (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Retained Earnings over the past 10 years, most recently at -$436.7 million for Q4 2023.

  • For Q4 2023, Retained Earnings fell 11.38% year-over-year to -$436.7 million; the TTM value through Dec 2023 reached -$436.7 million, down 11.38%, while the annual FY2023 figure was -$436.7 million, 11.38% down from the prior year.
  • Retained Earnings for Q4 2023 was -$436.7 million at Corbus Pharmaceuticals Holdings, down from -$8035.0 in the prior quarter.
  • Over five years, Retained Earnings peaked at -$8035.0 in Q3 2023 and troughed at -$436.7 million in Q4 2023.
  • A 5-year average of -$218.4 million and a median of -$241.5 million in 2020 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: soared 99.99% in 2021 and later plummeted 1248538.99% in 2022.
  • Year by year, Retained Earnings stood at -$192.8 million in 2019, then plummeted by 57.71% to -$304.1 million in 2020, then fell by 15.01% to -$349.7 million in 2021, then fell by 12.11% to -$392.1 million in 2022, then decreased by 11.38% to -$436.7 million in 2023.
  • Business Quant data shows Retained Earnings for CRBP at -$436.7 million in Q4 2023, -$8035.0 in Q3 2023, and -$418.6 million in Q2 2023.